Patterson Cos' Strong Q4 Earnings and Intel's Strategic Sale Shake the Market
- June 21st, 2023
- 465 views
Patterson Companies, Inc. (Nasdaq: PDCO), a leading provider of products and services to the dental, animal health, and rehabilitation markets, announced strong fourth-quarter fiscal 2023 earnings. The company reported earnings per share (EPS) of $0.84, surpassing the consensus estimate of $0.70.
Looking ahead to its full-year fiscal 2024, Patterson Companies expects continued growth and anticipates adjusted EPS to be in the range of $2.45 to $2.55. This outlook also exceeds market expectations, with the consensus estimate for the period at $2.34.
In pre-market, $PDCO is currently trading at $31.59, experiencing a notable increase of $3.33 (+11.78%)
In other news, Intel Corporation (Nasdaq: INTC) has announced an agreement to sell a 20% stake in its IMS Nanofabrication GmbH (IMS) business to Bain Capital Special Situations.
This transaction values IMS at approximately $4.3 billion and is expected to be completed in the third quarter of 2023. Following the sale, IMS will operate as a separate subsidiary and will continue to be led by CEO Dr. Elmar Platzgummer.
This strategic move by Intel aims to accelerate the advancement of critical multi-beam mask writing tools and foster greater collaboration across industries. Multi-beam mask writing tools play a vital role in the semiconductor ecosystem, particularly in the development of Extreme Ultraviolet (EUV) technology.
$INTC is trading at $34.75 in pre-market, down $0.25 (0.71%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026




Member Login